RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
-$79M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
+$15.7M |
| 2 |
Eli Lilly
LLY
|
+$12.6M |
| 3 |
Encompass Health
EHC
|
+$12.1M |
| 4 |
Cardinal Health
CAH
|
+$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
+$19.8M |
| 2 |
Oscar Health
OSCR
|
+$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
+$14.9M |
| 4 |
UnitedHealth
UNH
|
+$14.7M |
| 5 |
McKesson
MCK
|
+$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$672B
| $45.1M | 5.7% |
57,870
+16,120
| +39% | +$12.6M |
|
2
Boston Scientific
BSX
$155B
| $31.8M | 4.02% |
296,000
-4,000
| -1% | -$430K |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $27.4M | 3.46% |
61,455
-5,295
| -8% | -$2.36M |
|
4
Glaukos
GKOS
$5.05B
| $24.3M | 3.07% |
235,000
-35,000
| -13% | -$3.62M |
|
5
Intuitive Surgical
ISRG
$163B
| $24.1M | 3.05% |
44,350
-7,150
| -14% | -$3.89M |
|
6
Tenet Healthcare
THC
$17B
| $24M | 3.04% |
136,429
+9,729
| +8% | +$1.71M |
|
|
7
Danaher
DHR
$140B
| $24M | 3.03% |
121,452
+79,500
| +190% | +$15.7M |
|
8
CVS Health
CVS
$92.6B
| $20.4M | 2.58% |
295,362
+59,500
| +25% | +$4.1M |
|
|
9
McKesson
MCK
$87B
| $20.3M | 2.57% |
27,717
-19,500
| -41% | -$14.3M |
|
|
10
Neurocrine Biosciences
NBIX
$14.1B
| $18.8M | 2.37% |
149,217
+59,400
| +66% | +$7.47M |
|
11
Gilead Sciences
GILD
$143B
| $18.6M | 2.36% |
168,150
-65,350
| -28% | -$7.25M |
|
12
Exact Sciences
EXAS
$10.3B
| $18.6M | 2.35% |
350,000
-90,000
| -20% | -$4.78M |
|
13
Alignment Healthcare
ALHC
$3.25B
| $18M | 2.28% |
1,287,284
-50,000
| -4% | -$700K |
|
14
Insmed
INSM
$30.6B
| $17.7M | 2.23% |
175,435
-10,065
| -5% | -$1.01M |
|
15
Elevance Health
ELV
$69B
| $17.4M | 2.2% |
44,650
-4,300
| -9% | -$1.67M |
|
|
16
Encompass Health
EHC
$12.5B
| $16.7M | 2.11% |
136,400
+99,000
| +265% | +$12.1M |
|
17
Alnylam Pharmaceuticals
ALNY
$61.7B
| $16.7M | 2.11% |
51,197
+3,000
| +6% | +$978K |
|
18
Medtronic
MDT
$118B
| $15.6M | 1.98% |
179,500
-75,500
| -30% | -$6.58M |
|
19
Cencora
COR
$57.4B
| $14.8M | 1.87% |
49,375
+17,000
| +53% | +$5.1M |
|
20
Regeneron Pharmaceuticals
REGN
$58.9B
| $14.5M | 1.84% |
27,700
-4,050
| -13% | -$2.13M |
|
21
Insulet
PODD
$24B
| $14.5M | 1.83% |
46,000
-15,000
| -25% | -$4.71M |
|
22
DexCom
DXCM
$29.9B
| $13.9M | 1.76% |
159,500
+4,500
| +3% | +$393K |
|
23
AbbVie
ABBV
$372B
| $12.9M | 1.63% |
69,375
-19,275
| -22% | -$3.58M |
|
24
Align Technology
ALGN
$9.78B
| $12.6M | 1.59% |
66,500
+25,000
| +60% | +$4.73M |
|
25
Royalty Pharma
RPRX
$15.8B
| $12.4M | 1.57% |
344,000
-67,000
| -16% | -$2.41M |
|